{
    "nct_id": "NCT03269136",
    "official_title": "MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)",
    "inclusion_criteria": "* Relapsed/refractory multiple myeloma\n* Progressed or are intolerant of established therapies including proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody\n* Performance Status of 0- 1 ( Performance Score 2 is permitted only if due to underlying myeloma)\n* Adequate bone marrow, hematological, kidney and liver function\n* Resolved acute effects of any prior therapy to baseline severity\n* Not pregnant\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recent history of other malignancies\n* History of active autoimmune disorders\n* Any form of primary immunodeficiency\n* Active and clinically significant bacterial, fungal, or viral infection\n* Evidence of active mucosal or internal bleeding\n* History of severe immune-mediated adverse event with prior immunomodulatory treatment\n* Major surgery within 4 weeks of study treatment start\n* Radiation therapy within 2 weeks of study treatment start\n* History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment\n* Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry\n* Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy\n* Requirement for systemic immune suppressive medication except as permitted in the protocol\n* Current requirement for chronic blood product support",
    "miscellaneous_criteria": ""
}